FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Lebwohl

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Drug Administration Schedule

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
James C Yao; Catherine Lombard-Bohas; Eric Baudin; Larry K Kvols; Philippe Rougier; Philippe Ruszniewski; Sakina Hoosen; Jessica St Peter; Tomas Haas; David Lebwohl; Eric Van Cutsem; Matthew H Kulke; Timothy J Hobday; Thomas M O'Dorisio; Manisha H Shah; Guillaume Cadiot; Gabriele Luppi; James A Posey; Bertram Wiedenmann
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Eva Thomas; Josep Tabernero; Monica Fornier; Pierfranco Conté; Pierre Fumoleau; Ana Lluch; Linda Vahdat; Craig A Bunnell; Howard A Burris; Patrice Viens; José Baselga; Edgardo Rivera; Valentina Guarneri; Valerie Poulart; Judith Klimovsky; David Lebwohl; Miguel Martin
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Lebwohl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: James C Yao; Catherine Lombard-Bohas; Eric Baudin; Larry K Kvols; Philippe Rougier; Philippe Ruszniewski; Sakina Hoosen; Jessica St Peter; Tomas Haas; David Lebwohl; Eric Van Cutsem; Matthew H Kulke; Timothy J Hobday; Thomas M O'Dorisio; Manisha H Shah; Guillaume Cadiot; Gabriele Luppi; James A Posey; Bertram Wiedenmann
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(1):69-76.
2008: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet 2008;372(9637):449-56.
2007: Eva Thomas; Josep Tabernero; Monica Fornier; Pierfranco Conté; Pierre Fumoleau; Ana Lluch; Linda Vahdat; Craig A Bunnell; Howard A Burris; Patrice Viens; José Baselga; Edgardo Rivera; Valentina Guarneri; Valerie Poulart; Judith Klimovsky; David Lebwohl; Miguel Martin
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3399-406.
2006: Jaffer A Ajani; H Safran; C Bokemeyer; Manish A Shah; Heinz-Josef Lenz; E Van Cutsem; Howard A Burris; David Lebwohl; B Mullaney
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
Investigational new drugs 2006;24(5):441-6.
2002: Suzanne Jones; John Hainsworth; Howard A Burris; Dana Thompson; Eric A Raefsky; Valerie Johnson; Sharon Calvert; Cecile Bulanhagui; David Lebwohl; F Anthony Greco
Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies.
Investigational new drugs 2002;20(1):55-61.
1999: Clifford Hudis; Monica Fornier; L Riccio; David Lebwohl; John Crown; Teresa A Gilewski; A Surbone; Violante E Currie; Andrew D Seidman; B Reichman; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; Maria Theodoulou-Haber; L Weiselberg; R Salvaggio; Katherine S Panageas; Tzy-Jyun Yao; Larry Norton
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1118.
1999: Clifford Hudis; Andrew D Seidman; José Baselga; G Raptis; David Lebwohl; Teresa A Gilewski; Mary Ellen Moynahan; Nancy T Sklarin; DW Fennelly; John Crown; A Surbone; M Uhlenhopp; Elyn Riedel; Tzy-Jyun Yao; Larry Norton
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):93-100.
1998: Clifford Hudis; L Riccio; Andrew D Seidman; José Baselga; Violante E Currie; DW Fennelly; Teresa A Gilewski; David Lebwohl; Mary Ellen Moynahan; G Raptis; A Surbone; Nancy T Sklarin; Tzy-Jyun Yao; Deborah Keefe; Larry Norton
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.
Cancer investigation 1998;16(2):67-71.
1996: Clifford Hudis; Andrew D Seidman; G Raptis; DW Fennelly; Teresa A Gilewski; José Baselga; Maria Theodoulou-Haber; Nancy T Sklarin; Mary Ellen Moynahan; A Surbone; Violante E Currie; David Lebwohl; M Uhlenhopp; John Crown; Larry Norton
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Seminars in oncology 1996;23(1 Suppl 1):58-64.
1996: Clifford Hudis; Andrew D Seidman; John Crown; Casilda Balmaceda; R Freilich; Teresa A Gilewski; T B Hakes; Violante E Currie; David Lebwohl; José Baselga; G Raptis; Marc J Gollub; M Robles; R Bruno; Larry Norton
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):58-65.
1995: Clifford Hudis; Andrew D Seidman; José Baselga; G Raptis; David Lebwohl; Teresa A Gilewski; Violante E Currie; Mary Ellen Moynahan; Nancy T Sklarin; DW Fennelly
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Seminars in oncology 1995;22(6 Suppl 15):18-23.
1995: J M Bentel; David Lebwohl; Kevin J Cullen; M S Rubin; Neal Rosen; J Mendelsohn; W H Miller
Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells.
Journal of cellular physiology 1995;165(1):212-21.
1995: Laura Sepp-Lorenzino; Z Ma; David Lebwohl; A Vinitsky; Neal Rosen
Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases.
The Journal of biological chemistry 1995;270(28):16580-7.
1994: Laura Sepp-Lorenzino; Neal Rosen; David Lebwohl
Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(10):1077-83.
1994: Andrew D Seidman; Larry Norton; B S Reichman; John Crown; Tzy-Jyun Yao; T B Hakes; David Lebwohl; Teresa A Gilewski; Clifford Hudis; A Surbone
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.
Oncology 1994;51 Suppl 1():33-9.
1994: David Lebwohl; Robin C Muise-Helmericks; Laura Sepp-Lorenzino; S Serve; M Timaul; R Bol; Patrick I Borgen; Neal Rosen
A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line.
Oncogene 1994;9(7):1925-9.
1994: T F Anelli; A Anelli; KN Tran; David Lebwohl; Patrick I Borgen
Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients.
Cancer 1994;74(1):74-7.
1993: B S Reichman; Andrew D Seidman; John Crown; Robert T Heelan; Tzy-Jyun Yao; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report.
Annals of the New York Academy of Sciences 1993;698():398-402.
1993: B S Reichman; Andrew D Seidman; John Crown; Robert T Heelan; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie; Clifford Hudis
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1943-51.
1993: Andrew D Seidman; Larry Norton; B S Reichman; John Crown; Tzy-Jyun Yao; Robert T Heelan; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.
Seminars in oncology 1993;20(4 Suppl 3):40-5.
1993: John Crown; T Hakes; B Reichman; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie; Tzy-Jyun Yao; Clifford Hudis; Andrew D Seidman
Phase II trial of carboplatin and etoposide in metastatic breast cancer.
Cancer 1993;71(4):1254-7.
1993: Andrew D Seidman; B S Reichman; John Crown; Tzy-Jyun Yao; Robert T Heelan; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.
Journal of the National Cancer Institute. Monographs 1993;(15):171-5.
1991: David Lebwohl; I Nunez; M Chan; O M Rosen
Expression of inducible membrane-anchored insulin receptor kinase enhances deoxyglucose uptake.
The Journal of biological chemistry 1991;266(1):386-90.
1988: O M Rosen; David Lebwohl
Polylysine activates and alters the divalent cation requirements of the insulin receptor protein tyrosine kinase.
FEBS letters 1988;231(2):397-401.
1988: R Herrera; David Lebwohl; A Garcia de Herreros; R G Kallen; O M Rosen
Synthesis, purification, and characterization of the cytoplasmic domain of the human insulin receptor using a baculovirus expression system.
The Journal of biological chemistry 1988;263(12):5560-8.
1987: C K Chou; T J Dull; D S Russell; R Gherzi; David Lebwohl; A Ullrich; O M Rosen
Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin.
The Journal of biological chemistry 1987;262(4):1842-7.